Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Low Intensity Focused Ultrasound for Patients With Fibromyalgia

6 novembre 2026 mis à jour par: Patrick Finan, PhD, University of Virginia

Early Feasibility Study of Low Intensity Focused Ultrasound Neuromodulation in Patients With Fibromyalgia

The overall goal of this study is to establish the safety and feasibility of low intensity transcranial focused ultrasound (liFU) stimulation for patients with fibromyalgia. We will also attempt to investigate the efficacy of liFU for pain and related symptoms and to compare whether liFU effects differ for people trained in different types of meditation.

Aperçu de l'étude

Description détaillée

Following informed consent (Session 1), participants will participate in a baseline assessment (Session 2), during which they will receive a full battery of questionnaires, as well as a task-based fMRI and a baseline CT scan (the latter used for brain mapping in preparation of the liFU intervention). They will also be randomized during this session. The study is divided into two phases; in Phase 1 they will undergo four virtual sessions of a meditation intervention (either Savoring Meditation or Slow Breathing Meditation), depending on their group allocation (Session 3 to Session 6). They will then receive another assessment composed of questionnaires and a task-based fMRI (Session 7). In Phase 2 they will receive the liFU intervention (Session 8 to Session 11). At Session 11, they will also receive a post-treatment assessment composed of questionnaires and a task-based fMRI. A follow-up assessment (Session 12) four weeks after their final liFU intervention will be composed of questionnaires.

Type d'étude

Interventionnel

Inscription (Estimé)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Claudia Denoue F Postdoctoral Researcher, M.D.
  • Numéro de téléphone: (434)-982-2281
  • E-mail: finanlab@uvahealth.org

Sauvegarde des contacts de l'étude

  • Nom: Sierra Clark Clinical Research Coordinator
  • Numéro de téléphone: (434)-982-2281
  • E-mail: finanlab@uvahealth.org

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Females aged 18-75 years
  • Physician-confirmed diagnosis of FM according to the 2016 American College of Rheumatology criteria.
  • Willingness and ability to comply with scheduled visits and study procedures

Exclusion Criteria:

  • History of major neurological disorders
  • Current unstable psychiatric disorders or severe current substance use disorders
  • Current prescription opioid use or self -reported use of opioids in the past 30 days prior to enrollment (other medications are allowed, but must be on stable dose for at least 4 weeks)
  • Contraindications to MRI
  • Pregnancy or breastfeeding
  • Current neuromodulation therapy
  • Current meditation practice
  • Current participation in another interventional trial that could confound outcomes
  • Cannot read and speak English
  • Prisoner or cognitively impaired individuals
  • Unwilling or unable to use the internet and/or internet-enabled device to complete study procedures
  • Unable or unwilling to comply with study protocols or otherwise determined by the PI to be able to safely participate in the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Low Intensity Focused Ultrasound + Savoring Meditation (liFU+SM)

In this arm, participants first receive training in Savoring Meditation, a positive affect-focused behavioral intervention designed to enhance positive affect and support chronic pain self-management. Participants complete four 20-minute telehealth training sessions over approximately two weeks delivered by a trained interventionist. After completing the meditation training portion, participants in the liFU + SM arm complete four sessions of low-intensity focused ultrasound targeting the nucleus accumbens during which they actively practice Savoring Meditation concurrent with the sonication.

Autres noms:
  • liFU + SM
Comparateur actif: Low Intensity Focused Ultrasound

In the liFU arm, participants first spend 4 telehealth sessions undergoing training in a slow breathing meditation practice. Subsequently, participants complete four in-person liFU treatment sessions over four weeks, with sequential bilateral sonications targeting the nucleus accumbens during each session. In this arm, participants do not engage in any concurrent meditation practice or other behavioral intervention during sonication. Rather, they only receive liFU sonication during those sessions.

Autres noms:
  • liFU

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Safety of liFU intervention
Délai: At Session 7 (Week 3), at Sessions 8-11 (Weeks 3-6; immediately before and after each intervention and 24h after each intervention), weekly throughout weeks 7-11 and at Session 12 (Week 11).

Number of treatment-related unexpected adverse events and serious adverse events

At Session 7 (Week 3), at Sessions 8-11 (Weeks 3-6; immediately before and after each intervention and 24h after each intervention), weekly throughout weeks 7-11 and at Session 12 (Week 11).
Study recruitment rate
Délai: Assessed from screening (Session 1; week -1) to enrollment (Session 2; week 0).

Number of participants enrolled divided by number screened.

Assessed from screening (Session 1; week -1) to enrollment (Session 2; week 0).
Study adherence
Délai: Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

Number of participants to complete all Phase 1 and Phase 2 intervention sessions

Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).
Study retention
Délai: Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

Number of enrolled participants retained through the entirety of the study

Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Nucleus accumbens activation
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).

Change in blood-oxygen-level-dependent (BOLD) signal in the nucleus accumbens, measured using functional MRI during a task that pairs meditation with noxious thermal stimulation, relative to rest. Changes will be compared between the liFU + Savoring Meditation and liFU arms.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
Change in nucleus accumbens-ventromedial prefrontal cortex functional connectivity
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).

Change in functional connectivity between the nucleus accumbens (NAc) and ventromedial prefrontal cortex (vmPFC), measured using functional MRI during a task that pairs meditation with noxious thermal stimulation, relative to rest. Changes will be compared between the liFU + Savoring Meditation and liFU arms.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
Clinical pain impact
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in clinical pain impact will be evaluated using the Pain, Enjoyment of life, and General activity (PEG) Scale, which is a hybrid measure of pain severity and pain interference. This scale is comprised of 3 items, each rated on a numerical scale from 0-10. The total score is averaged on a scale from 0-10.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Clinical pain severity
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), Sessions 8-11 (Weeks 3-6; immediately after each intervention and 24h after each intervention), weekly throughout weeks 7-11, and Session 12 (week 11).

Changes in clinical pain severity will be evaluated using the Brief Pain Inventory (BPI). Average pain in the past 24 hours is rated on a scale from 0-10.

Assessed at Session 2 (week 0), Session 7 (week 3), Sessions 8-11 (Weeks 3-6; immediately after each intervention and 24h after each intervention), weekly throughout weeks 7-11, and Session 12 (week 11).
Pain catastrophizing
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in pain catastrophizing will be evaluated using the Pain Catastrophizing Scale (PCS). The PCS is a 13-item scale, each noted on a Likert like scale from 0-4. Total scores are obtained by summing all scores, to obtain a score between 0 and 52.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Fatigue
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in fatigue levels will be evaluated using the Fatigue Severity Scale (FSS). The FSS is a 9-item scale, each noted on a Likert like scale from 1-7. Total scores are obtained by summing all scores, to obtain a score between 0 and 63.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Fibromyalgia Impact
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Fibromyalgia Impact will be assessed using the Fibromyalgia Impact Questionnaire Revised (FIQ-R). The FIQ-R is a 21-item scale where each item is rated on a scale from 0-10 and the overall score is calculated as the addition of all items and then normalized relative to a predefined level of importance for each item. Total scores range from 0-100.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Fibromyalgia Severity
Délai: Assessed at Session 2 (week 0) and Session 7 (week 3).

Fibromyalgia Severity will be assessed with the Widespread Pain Index (WPI) and the Symptom Severity Scale (SSS). The WPI counts the number of tender points reported and can range from 0 to 19. The SSS assesses 3 items on a Likert-like scale (from 0-3) as well as 3 items on a binary Yes/No scale (Yes=1, No=0). The SSS scale yields a score ranging from 0-12. In total, the WPI-SSS score is calculated by adding the WPI and the SSS score, yielding a final total score ranging from 0-31.

Assessed at Session 2 (week 0) and Session 7 (week 3).
Sleep quality
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Sleep quality will be assessed using the Insomnia Severity Index (ISI) and the Pittsburgh Sleep Quality Index (PSQI). The ISI is a 7-item Likert-like scale (ranging from 0-4). The total score is obtained by adding all item scores, yielding a total possible range of 0-28. The PSQI is a scale comprising of 7 different components, each of which may range from 0-3. The total score is obtained by adding all component scores, yielding a total possible range of 0-21.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Positive Affect
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in Positive Affect will be assessed using the Positive and Negative Affect Schedule - Expanded Form (PANAS-X). The PANAS-X consists of 60 items rated on a Likert-like scale (ranging from 1-5). Total scores are separated as General negative affective scores (ranging 10-50), General Positive Affective Scores (ranging 10-50) and a series of emotional scales with varying ranges.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Hedonic Capacity
Délai: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item scale where each item is rated on a Likert-like scale ranging from 0-3. Total scores are obtained by adding each item, yielding a total score ranging from 0-42.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Patrick Finan Finan, PhD, Department of Anesthesiology, University of Virginia

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

15 janvier 2027

Achèvement primaire (Estimé)

15 janvier 2029

Achèvement de l'étude (Estimé)

1 avril 2029

Dates d'inscription aux études

Première soumission

3 novembre 2026

Première soumission répondant aux critères de contrôle qualité

6 novembre 2026

Première publication (Réel)

13 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

6 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • HSR 303312

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner